Literature DB >> 18093410

The SCORE model in the POWER study: an attempt to focus the limited resources for prevention on patients with greatest need.

Guy De Backer1.   

Abstract

As the emergence of cardiovascular disease (CVD) is linked to modifiable lifestyle and physiological factors, it is increasingly important to concentrate on preventative strategies. For preventative measures to be beneficial it is necessary to clearly identify patients at risk--given that multiple risk factors often cluster this requires the assessment of total cardiovascular (CV) risk. Total CV risk can be estimated in different ways; in the guidelines on the management of arterial hypertension by a Joint Task Force of the European Society of Hypertension and the European Society of Cardiology a categorical approach was recommended. A model based on results from the US Framingham study has been available for many years. Systemic COronary Risk Evaluation (SCORE) is a recently developed total CV risk assessment model, based on approximately 3 million person-years of observation, which estimates fatal CVD events over a 10-year period, incorporating both coronary heart disease and cerebrovascular disease. The SCORE model aids clinicians in their decision on how to engage in preventative measures and how to adjust the intensity of their preventative efforts in accordance with the total CV risk of the patient. The SCORE model has been incorporated into the Physicians Observational Work on Patient Education According to their Vascular Risk (POWER) study. This study, with an estimated sample size of 60,000 patients, will determine if SCORE can act as a suitable tool to aid the lowering of CV risk.

Entities:  

Mesh:

Year:  2007        PMID: 18093410     DOI: 10.1185/030079907X260728

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  2 in total

Review 1.  Eprosartan: a review of its use in hypertension.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  Effect of eprosartan-based therapy on systolic blood pressure and total cardiovascular risk in a large international population: preliminary report of the observational POWER study.

Authors:  Assen Goudev; Jean-Pascal Berrou; Atul Pathak
Journal:  Vasc Health Risk Manag       Date:  2012-09-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.